# Syndax Pharmaceuticals Inc: overview

SNDX · Nasdaq · CIK 1395937 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sndx.md) · [Financials](/companies/sndx/financials.md) · [Filings](/companies/sndx/filings.md) · [Insiders](/companies/sndx/insiders.md)

Latest reported revenue: [$72.8m](/filings/0001193125-26-332750.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-332750).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.5](/filings/0001193125-25-262521.md) | [7.7 d](/filings/0001193125-26-076536.md) | [20.0](/filings/0001193125-26-197154.md) | [38.0](/filings/0001193125-26-332750.md) | [45.9](/filings/0001193125-25-262521.md) | [68.7 d](/filings/0001193125-26-076536.md) | [64.9](/filings/0001193125-26-197154.md) | [72.8](/filings/0001193125-26-332750.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(716.6%)](/filings/0001193125-25-262521.md) | [(1254.8%) d](/filings/0001193125-26-076536.md) | [(417.9%)](/filings/0001193125-26-197154.md) | [(182.7%)](/filings/0001193125-26-332750.md) | [(125.2%)](/filings/0001193125-25-262521.md) | [(91.0%) d](/filings/0001193125-26-076536.md) | [(52.7%)](/filings/0001193125-26-197154.md) | [(54.9%)](/filings/0001193125-26-332750.md) |
| Net margin | % | [(673.0%)](/filings/0001193125-25-262521.md) | [(1226.2%) d](/filings/0001193125-26-076536.md) | [(423.3%)](/filings/0001193125-26-332750.md) | [(189.3%)](/filings/0001193125-26-332750.md) | [(132.4%)](/filings/0001193125-25-262521.md) | [(99.0%) d](/filings/0001193125-26-076536.md) | [(65.8%)](/filings/0001193125-26-332750.md) | [(67.8%)](/filings/0001193125-26-332750.md) |
| Diluted EPS | $ per share | [(0.98)](/filings/0001193125-25-262521.md) | not reported | [(0.98)](/filings/0001193125-26-197154.md) | [(0.83)](/filings/0001193125-26-332750.md) | [(0.70)](/filings/0001193125-25-262521.md) | not reported | [(0.48)](/filings/0001193125-26-197154.md) | [(0.55)](/filings/0001193125-26-332750.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [140](/filings/0000950170-24-021253.md) | [0.0](/filings/0000950170-25-030394.md) | [0.0](/filings/0001193125-26-076536.md) | [23.7](/filings/0001193125-26-076536.md) | [172](/filings/0001193125-26-076536.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [18.8%](/filings/0000950170-24-021253.md) | not reported | not reported | [(1434.4%)](/filings/0001193125-26-076536.md) | [(158.4%)](/filings/0001193125-26-076536.md) |
| Net margin | % | [17.8%](/filings/0000950170-24-021253.md) | not reported | not reported | [(1346.1%)](/filings/0001193125-26-076536.md) | [(165.6%)](/filings/0001193125-26-076536.md) |
| Diluted EPS | $ per share | [0.46](/filings/0000950170-24-021253.md) | [(2.46)](/filings/0000950170-25-030394.md) | [(2.98)](/filings/0001193125-26-076536.md) | [(3.72)](/filings/0001193125-26-076536.md) | [(3.29)](/filings/0001193125-26-076536.md) |
| Free cash flow | $m | [29.0](/filings/0000950170-24-021253.md) | [(134)](/filings/0000950170-25-030394.md) | [(161)](/filings/0001193125-26-076536.md) | [(275)](/filings/0001193125-26-076536.md) | [(323)](/filings/0001193125-26-076536.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sndx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $197.2m | 9,020,006 |  | Added +765,580 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $176.0m | 8,050,959 |  | Unchanged |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $128.1m | 5,861,265 |  | Added +864,478 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $123.7m | 5,658,424 |  | Added +1,228,348 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $88.4m | 4,045,094 |  | Reduced −204,742 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $85.9m | 3,927,892 |  | Added +105,313 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $82.6m | 3,779,900 |  | Unchanged |
| [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $61.2m | 2,798,210 |  | Reduced −87,412 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.5m | 2,584,136 |  | Added +427,078 |
| [Hood River Capital Management LLC](/funds/1578177.md) | 2026-06-30 | $56.1m | 2,564,279 |  | Added +209,994 |

## Recent filings

[All 640 filings](/companies/sndx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:04 ET | [10-Q](/filings/0001193125-26-332750.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332750 |
| 2026-08-04 | 16:02 ET | [8-K](/filings/0001193125-26-332736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332736 |
| 2026-07-14 | 08:30 ET | [8-K](/filings/0001193125-26-302608.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-302608 |
| 2026-06-10 | 17:04 ET | [8-K](/filings/0001193125-26-266027.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-266027 |
| 2026-06-10 | 16:15 ET | [8-K](/filings/0001193125-26-265852.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265852 |
| 2026-06-04 | 07:16 ET | [8-K](/filings/0001193125-26-256458.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-256458 |
| 2026-04-30 | 17:20 ET | [DEF 14A](/filings/0001193125-26-197859.md) | Proxy statement, period 2026-04-30 | 0001193125-26-197859 |
| 2026-04-30 | 16:04 ET | [10-Q](/filings/0001193125-26-197154.md) | Quarterly report, period 2026-03-31 | 0001193125-26-197154 |
| 2026-04-30 | 16:02 ET | [8-K](/filings/0001193125-26-197124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197124 |
| 2026-02-26 | 16:04 ET | [10-K](/filings/0001193125-26-076536.md) | Annual report, period 2025-12-31 | 0001193125-26-076536 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076536.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/40338f0b-341d-4a59-82ff-003a404fe829)

## About the filer

- CIK: 1395937
- Tickers: SNDX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 19:11 ET. No prices; not investment advice.